AstraZeneca and Stone Pharmaceutical Group reach nearly $2 billion cardiovascular drug authorization protocol

On October 7th, Jin10 News reported that AstraZeneca and Chi-Med (01093.HK) have reached an exclusive licensing protocol to advance the development of a preclinical innovative small molecule lipoprotein(a) (Lp(a)) inhibitor to enhance the cardiovascular product pipeline. AstraZeneca said it will pay Chi-Med up to $1.92 billion in milestone and royalty payments and $100 million in upfront payment.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)